The study, led by researchers at The Affiliated Central Hospital of Dalian University of Technology and published in BMC Cancer, followed 920 women who had survived at least five years after their ovarian cancer diagnosis. Rather than tracking them from diagnosis, the investigators anchored all follow-up at the fifth anniversary of the diagnosis, a technique known as a landmark analysis. Each woman entered the analysis at the later of that anniversary and her UK Biobank enrollment, ensuring that the risk estimates reflect mortality genuinely occurring in the survivorship period rather than deaths that happened before the landmark. Of the 920 survivors, 845 also had whole-exome sequencing data available, allowing the team to probe whether inherited variants in DNA repair genes shaped long-term outcomes.

During post-entry follow-up, 322 deaths occurred among the survivors. The largest share, 183 deaths, was attributable to ovarian cancer itself. Cardiovascular disease claimed 58 lives, second primary malignancies 42, and other non-cancer causes 39. To quantify these risks properly, the researchers used the Aalen–Johansen estimator to compute cause-specific cumulative incidence, a statistical approach that accounts for competing risks, meaning that a woman who dies of a heart attack can no longer die of ovarian cancer, so treating all deaths as equal would distort the picture. Five years after the survivorship landmark, the cumulative incidence of ovarian cancer death stood at 15.6 percent, while the combined incidence of all competing causes of death was 7.5 percent.

The gap between those two figures is statistically striking. The adjusted risk difference was minus 8.1 percentage points, with a 95 percent confidence interval running from minus 10.4 to minus 5.8, indicating that ovarian cancer mortality remained firmly predominant among five-year survivors as a whole. For the clinical community, this is a sobering counterpoint to the optimism that often accompanies the five-year survival milestone. It suggests that ovarian cancer survivors need continued, disease-focused surveillance well beyond the period when most follow-up schedules begin to taper off, and that late recurrence or progression remains a dominant threat even in a population often informally considered cured.

Yet the study also reveals that this predominance is not uniform. When the researchers stratified their analysis, the advantage of ovarian cancer death over competing causes weakened and the confidence intervals came to include zero among three groups: survivors aged 65 or older, those carrying more than two comorbid conditions, and those living in the highest tertile of socioeconomic deprivation. In other words, among older, sicker, and poorer survivors, deaths from cardiovascular disease and other non-cancer causes become nearly as likely as deaths from the original cancer. This finding reframes survivorship care as a genuinely multidisciplinary enterprise, one in which cardiometabolic health and social circumstances matter alongside oncological surveillance.

The risk factors for each cause of death followed distinct patterns. Advanced stage and serous histology, the most aggressive and common subtype of ovarian cancer, were associated mainly with ovarian cancer mortality, reflecting the biological behavior of the malignancy itself. By contrast, older age, greater deprivation, a higher comorbidity burden, adiposity, and current smoking were linked primarily to cardiovascular mortality. The comorbidity effect was particularly dramatic: women with more than two comorbidities had a subdistribution hazard ratio of 3.32 for cardiovascular death, with a 95 percent confidence interval of 1.86 to 5.92, meaning their risk was more than triple that of women with fewer coexisting conditions. These are modifiable or manageable factors, which gives the finding practical weight for clinicians designing survivorship programs.

Perhaps the most intriguing result came from the genomic analysis. Carriers of germline variants in homologous recombination repair genes, the same family of genes that includes BRCA1 and BRCA2 and that has long been known to raise ovarian cancer risk, faced markedly higher mortality from second primary malignancies than non-carriers. The subdistribution hazard ratio was 3.74, with a 95 percent confidence interval of 1.88 to 7.42. Homologous recombination repair is a cellular mechanism that fixes double-strand breaks in DNA, and inherited defects in this pathway impair the body’s ability to prevent cancer-causing mutations from accumulating. The new data suggest that this vulnerability does not disappear after an initial cancer diagnosis; instead, it continues to expose survivors to elevated risk of entirely new malignancies over the long term.

The authors themselves flag an important caveat: that genomic estimate rests on few events, so it should be interpreted as hypothesis-generating rather than definitive. Even so, the finding points toward a future in which germline genetic status becomes part of routine survivorship risk stratification. Women carrying HRR variants might warrant intensified screening for second cancers, while the broader survivor population could benefit from aggressive management of cardiovascular risk factors such as smoking, obesity, and coexisting chronic disease. Because many chemotherapy regimens, including platinum agents used widely in ovarian cancer, can themselves stress the cardiovascular system, the high comorbidity and adiposity signals in the data underscore how treatment and lifestyle interact over decades.

The methodology deserves attention as well. Competing-risk statistics such as the Fine–Gray and cause-specific Cox models used here are often absent from survivorship studies, which frequently report all-cause mortality and thereby blur together deaths from fundamentally different mechanisms. By separating ovarian cancer deaths from cardiovascular, second-cancer, and other deaths, and by quantifying cumulative incidence with proper confidence intervals, this study provides a template for how large biobank-linked cohorts can generate clinically actionable survivorship evidence. The use of linked UK Biobank data, with its combination of clinical records, socioeconomic indicators, biochemical measurements, and whole-exome sequencing, is what made the multimodal risk analysis possible in the first place.

The broader message for the estimated hundreds of thousands of women worldwide living beyond five years after ovarian cancer is twofold. First, vigilance against the original cancer remains justified; ovarian cancer was still the single largest cause of late death in this cohort, with a cumulative incidence nearly twice that of all competing causes combined. Second, survivorship is not only about cancer. Older survivors, those with multiple chronic conditions, and those facing socioeconomic deprivation face cardiovascular risks that rival their oncological ones, and inherited DNA repair defects quietly raise the specter of new cancers decades later. Tailored, risk-stratified follow-up, informed by stage, histology, comorbidity, deprivation, and genotype, could convert these statistical insights into longer and healthier lives for a growing population of long-term survivors.

Subject of Research: Cause-specific mortality patterns and clinical, genomic, biochemical, and socioeconomic risk determinants among five-year ovarian cancer survivors

Article Title: Cause-specific mortality and multimodal risk determinants among 5-year ovarian cancer survivors

Article References: Yang, Y., Wang, Y., Jiao, Y., & Wang, J. (2026). Cause-specific mortality and multimodal risk determinants among 5-year ovarian cancer survivors. BMC Cancer. https://doi.org/10.1186/s12885-026-16866-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16866-7

Keywords: ovarian cancer, cancer survivorship, cause-specific mortality, competing risks, homologous recombination repair, cardiovascular mortality, second primary malignancy, UK Biobank, comorbidity, socioeconomic deprivation, Fine-Gray model, Aalen-Johansen estimator